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Stent thrombosis (TS) after percutaneous coronary intervention (PCI) is a rare but 
potentially fatal complication with an incidence of 1% to over 5%. Risk factors for TS can 
be divided into factors related to the patient, procedure, stent type and characteristics of 
the lesion. 
One thousand fifty-five patients who underwent PCI during 2009 and 2010 were 
included into the study and followed during the next year. Patients with and without 
definite TS formed the study (TS+) and control group (TS+), respectively. 
Twenty-three patients had TS (2,2%). Early, late and very late TS were noted in 
69,5%, 13,1% and 17,4% of patients, respectively. Acute myocardial infarction with ST-
segment elevation was the most frequent clinical presentation (56,6%). Discontinuation 
of aspirin and/or clopidogrel (34.8%) and resistance to these drugs (34.7%) were the 
main patient-related factors for TS. A higher percentage of stenosis of lesions (92 ± 12 
vs 86 ± 14), greater average stent length (19.69 vs 17.01 mm), lower pressure stent 
insufflation (14.84 vs. 16.02 atm) and coronary artery dissection (26.1%) were 
significant reasons for the occurrence of TS. Similar stent type -  BMS („bare metal 
stents) and DES („drug eluting stents“) were applied in both of patient groups.  
STEMI patients and those with impaired systolic left ventricular function are at 
highest risk of TS, which is reported in more than two thirds of them in the first 30 days 
after PCI. Discontinuation of aspirin and/or clopidogral or resistance to these drugs led 
to TS. Greater stent length,  small diameter of the stent ("underestimated lesion"), 
lower pressure insufflation and dissection of the coronary artery are the most common 
procedural reasons for the occurrence of TS. Type of stent (BMS and DES) had no 
significant effect on the occurrence of TS. Acta Medica Medianae 2013;52(4):5-11. 
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Introduction 
 
   Stent thrombosis (TS) after percutaneous 
coronary intervention (PCI) is a rare but poten-
tially fatal complication. The rate of TS in the 
literature varies from one study to another, 
ranging from 1% to over 5% (1-4). This variation 
in the incidence of TS is caused due to several 
reasons including the definition of TS, stent type, 
time when the study was conducted, type and 
duration of application of antiplatelet therapy, 
relationship between patients with stable angina 
pectoris (SAP) and patients with acute coronary 
syndrome (ACS) etc. Risk factors for TS can be 
divided into factors related to the patient, 
procedure, stent type and characteristics of the 
lesion. The patient-related factors are: interrup-
tion of antiplatelet therapy, resistance to anti-
platelet therapy, diabetes mellitus, renal failure 
and ACS. The procedure-related factors are: proce-
dural complications (eg., coronary artery dissec-
tion), inadequate size of the stent or inadequate 
stent implantation. The type of stent is the most 
important stent-related factor: BMS (bare metal 
stents) or drug-coated stents - DES (drug-eluting 
stets). 
 
Aims  
 
The aim of this paper is to present the 
incidence, clinical, angiographic, and procedural 
characteristics of patients with TS in the real, 
everyday practice.  
 
Methods 
 
The study included 1.055 consecutive patients 
who underwent PCI from July 2009 to June 2010 
who were followed for the next two years, until 
the end of June 2012. PCI was performed for Clinical and angiographic characteristics of patients with stent thrombosis                                              Miodrag Damjanović et al. 
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patients with SAP (elective PCI), unstable angina 
pectoris (UAP) and non-Q myocardial infarction 
(NSTE-ACS), and patients with acute myocardial 
infarction with ST-segment elevation (STEMI). 
Twenty three patients with definite TS and 70 
patients without TS formed the study group (TS 
+) and control group (TS-), respectively, but the 
latter was chosen randomly. Definite TS was 
defined by the criteria of the ARC (Academic 
Research Consortium). Namely, TS must be 
confirmed by angiography in the form of partial 
or complete occlusion within a previously implan-
ted stent or in the segment 5mm proximal or 
distal to the stent and the presence of at least 
one of the following criteria: a new beginning 
acute ischemic symptoms at rest, new ECG 
changes indicating acute ischemia, or typical rise 
and fall of cardiac biomarkers. Stent thrombosis 
occurring 0 to 24 hours, >24 hours to 30 days, 
>30 days to 1 year and >1 year after stent 
implantation was defined as acute, subacute, late 
and very late, respectively (5). 
Three hundred and twenty-four patients, of 
the  total number of patients with PCI, had 
STEMI. Patients with SAP and NAPs had already 
been on dual antiplatelet therapy (DAPT) (aspirin 
100mg and clopidogrel 75mg daily), and if not, 
as well as patients with STEMI, at admission were 
prescribed aspirin 300mg and 600mg clopidogrel 
with standard heparin or enoxaparin, statin and 
the other therapy according to the guidelines for 
the treatment of NSTE-ACS and STEMI and 
revascularization (6). DAPT is recommended for 
one year to all patients with ACS and performed 
PCI. 
All patients had the basic laboratory tests 
performed (elective patients prior to admission), 
patients with ACS cardiospecific enzyms and 
troponin I too, ECG on admission and ECG series 
after that. Test of platelet aggregation (Multiplate 
analyzer, Dynabyte, Munich, Germany) was perfor-
med in all patients with TS, but not other patients 
with routine PCI, which showed resistance to 
aspirin and/or clopidogrel. 
Transthoracic echocardiography was done 
to ambulatory patients with SAP before PCI, and 
to patients with ACS on the device ALOKA Pro 
Sound 4000 before entering the cath lab. 
Diameter of stenosis was assessed visually 
on coronary angiography. Angiographic thrombus 
was defined as a filling defect seen in two or 
more projections surrounded by contrast. It is 
thought that the small diameter of the stent was 
deployed if at least one of the following criteria 
was met: the stent to  the reference segment 
coronary artery diameter ratio was <1, discrepancy 
between the stent and the line of the wall of 
coronary artery and mismatch of the stent size 
and proximal and distal segment artery in which 
PCI was performed (3). 
 
Table 1. Clinical characteristics of examined patients 
 
Variables  TS + 
(n=23) 
TS – 
(n=70)  p 
Age (years)  55,9 ± 10,7  57,8 ± 9,5  NS 
Male, n (%)  16 (69,6)  50 (71,4)  NS 
Presentation, n (%)      < 0,005 
SAP  9 (39,1)  46 (65,7)   
NSTE-ACS  1 (4,3)  10 (14,3)   
STEMI  13 (56,6)  14 (20)   
Risk factors for CAD, n (%)       
Smoking (current)  14 (60,9)  15 (21,4)  < 0,02 
Hypertension  15 (65,2)  50 (71,4)  NS 
Family history of CAD  11 (47,8)  33 (47,1)  NS 
Dyslipidemia  13 (56,5)  33 (47,1)  NS 
Diabetes mellitus  4 (17,4)  17 (24,3)  NS 
BMI (kg/m2)  27 ± 2,7  27,1 ± 3  NS 
CKD (eGRF<60ml/min./1,73m
2), n (%)  2 (8,7)  2 (2,9)  NS 
Prior MI, n (%)  10 (43,5)  30 (42,9)  NS 
NYHA ≥ 2, n (%)  9 (39,1)  12 (17,1)  < 0,02 
EF LV (%)  42,3 ± 8,1  49,8 ± 9,7  < 0,001 
Discontinuation of DAPT, n (%)       
Aspirin  1 (4,3)  -  NS 
Clopidogrel  6 (26,1)  -  < 0,001 
Aspirin + Clopidogrel  1 (4,3)  -  NS 
Resistance to DAPT, n (%)       
Aspirin  1 (4,3)  -  NS 
Clopidogrel  7 (30,4)  -  < 0,001 
SAP=stable angina pectoris, NSTE-ACS=acute coronary syndrome without ST-segemt nelevation, STEMI=acute 
myocardial infarction with ST-segment elevation, CAD=coronary artery disease, BMI=body mass index, 
CKD=chronic kidney disease, eGFR=estimated glomerular filtration rate, MI=myocardial infarction, NYHA=New 
York Heart Association class, EF=ejection fraction, LV=left ventricle, DAPT=dual antiplatelet therapy Acta Medica Medianae 2013, Vol.52(4)                             Clinical and angiographic characteristics of patients with stent thrombosis 
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Statistical analysis 
 
Data are presented as mean ± SD or as 
percentages (proportions). Statistical analysis was 
performed using Student's t-test for continuous 
variables. The Chi-square test and Fischer's exact 
probability test were used to analyze the 
differences in categorical variables. Values of p 
<0.05 were considered statistically significant. All 
statistical analyses were performed using SPSS 
version 16.0 (IBM, Armonk, NY, USA). 
 
Results  
 
1.  Clinical characteristics : During the study 
period  1.055 patients underwent PCI with stent 
implantation. Similar demographic characteristics 
and percentages of risk factors for coronary heart 
disease were noted in both groups, except for 
smoking, which was more frequently recorded in 
patients with TS+ (60.9 vs. 21.4%, p<0,02). 
STEMI was an indication for PCI more often in 
patients with TS+ (56.6% vs 20%, p<0.005) 
(Table 1). NYHA class  ≥ 2 (39.1% vs. 17.1%, p 
<0.02) and a lower left ventricular ejection 
fraction (EF) (42.3±8.1 vs 49.8±9.7, p<0.001) 
were noted more often in patients with TS+. 
Discontinuation of aspirin (4.3%) or clopidogrel 
(26.1%, p <0.001) or both of them (4.3%), as 
resistance to aspirin (4.3%) or clopidogrel (30,4%, 
p<0.001) were the main reasons for TS+ in more 
than 1/3 patients with TS+. 
 
Table 2. Angiographic characteristics of examined patients 
 
Variables  TS + 
(n=23) 
TS – 
(n=70)  p 
Coronary angiogram      NS 
Multivessel disease, n (%)  10 (43,5)  37 (52,9)   
LAD, n (%)  13 (56,5)  38 (54,3)   
LCx, n (%)  4 (17,4)  11 (15,7)   
RCA, n (%)  6 (26,1)  21 (30)   
No. of vessels with > 50% stenosis  1,5 ± 0,8  1,6 ± 0,8   
Left main disease, n (%)  1 (4,3)  6 (8,6)   
Lesion characteristics, n (%)       
A  1 (4,3)  4 (5,7)  NS 
B1  3 (13)  19 (27,1)  NS 
B2  14 (60,9)  31 (44,3)  NS 
C  5 (21,7)  16 (22,9)  NS 
Ostial segment  2 (8,7)  3 (4,3)  NS 
Proximal segment  15 (65,2)  25 (35,7)  < 0,05 
Medial  segment  4 (17,4)  40 (57,1)  < 0,001 
Distal  segment  2 (8,7)  2 (2,9)  NS 
TIMI flow before PCI      < 0,001 
TIMI 0  14 (60,9)  15 (21,4)   
TIMI 1  -  5 (7,1)   
TIMI 2  8 (34,8)  11 (15,7)   
TIMI 3  1 (4,3)  39 (55,8)   
Procedural characteristics       
Anticoagulation at PCI, n (%)      NS 
Heparin  17 (73,9)  64 (91,4)   
Enoxaparin  6 (26,1)  6 (8,6)   
No. of stented lesions, n (%)  1,09 ± 0,29  1,17 ± 0,42  NS 
% stenosis of stented lesions  92 ±12  86 ± 14  < 0,05 
No. of stents, n (%)  1,43 ± 0,79  1,41 ± 0,67  NS 
Stent length (mm)  19,69 ± 5,07  17,01 ± 5,85  < 0,05 
Stent diameter (mm)  2,87 ± 0,35  3 ± 0,42  NS 
Undersizing of the stent (“underestimated  
lesion”), n (%)  5 (21,7)  3 (4,3)  < 0,01 
Stent insufflation pressure (atm)  14,84 ± 2,68  16,02 ± 2,5  < 0,05 
Coronary artery dissection, n (%)  6 (26,1)  6 (8,6%)  < 0,005 
TIMI flow after PCI, n (%)      < 0,025 
TIMI 2  7 (30,4)  7 (10)   
TIMI 3  16 (69,6)  63 (90)   
Stent type, n (%)      NS 
BMS  16 (69,6)  51 (72,9)   
DES  7 (30,4)  19 (27,1)   
Type of intervention in TS+, n (%)       
PCI with stent deployment  11 (47,8)  -   
POBA  11 (47,8)  -   
Thrombus aspiration  1 (4,4)     
TS outcome, n (%)       
STEMI  22 (95,7)  -   
Death  1 (4,3)  -   
 
LAD=left anterior descending artery, LCx=left circumflex artery, RCA=right coronary artery, TIMI=Thrombolysis In 
Myocardial Infarction, POBA=Plain Old Balloon Angioplasty 
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Table 3. The incidence of TS according to ARC and type of the stent 
 
 
Type of TS, n (%) 
BMS 
n (%) 
DES 
n (%)  Totally 
Early (0-30 days)*       
Acute (≤24h)  8 (34,8)  -  8 (34,8) 
Subacute (>24h)  4 (17,4)  5 (21,7)  9 (39,1) 
Late (31-365 days)*
,†  -  2 (8,7)  2 (8,7) 
Very late (>365 days)*
,†  4 (17,4)  -  4 (17,4) 
Totally  16 (69,6)  7 (30,4)  23 (100,0) 
 
BMS vs DES/BMS+DES: *NS early vs late, late vs very late, early vs very late;
†p<0,05 late vs very late 
ARC= Academic Research Consortium 
 
2.  Angiographic characteristics: Definite 
TS+ was registered in 23 patients (2.2%). A total 
of 33 and 99 stents were applied in TS+ and TS- 
groups, respectively. Left main disease, multi-
vessel disease, the number of vessels with stenosis 
larger than 50%, the stented vessel, and the 
type of lesions did not differ significantly between 
the groups (Table 2). 
TS+ patients had more often TIMI 0 flow 
(60.9% vs 21.4%, p<0.001). The average number 
of stented lesions did not differ between the 
groups, but the percent of stenosis of treated 
lesions (92±12% vs 86±14%, p<0.05) and the 
average length of stent (19.69±5.07 vs. 17.01± 
5.85mm, p<0.05) were significantly larger in 
TS+ group. The average number of implanted 
stents did not differ among the groups, but stent 
diameter was smaller in TS+ group while smaller 
stents than optimal ("underestimated lesion") 
were more often delivered in TS+ group (21.7% 
vs 4.3%, p<0.01). The insufflation pressure 
(14.84±2.68 vs. 16.02±2.5atm, p<0.05) was 
lower in the TS+ group and coronary artery 
dissection was more often in TS+ group (26.1% 
vs. 8.6%, p<0.005). Similar type of stent (DES 
vs BMS) was deployed in both of groups. Chest 
pain and ST segment elevation (STEMI) appeared 
in the majority of TS+ patients and one death 
was reported (4.3%) 13 days after stent implan-
tation. 
BMS were the most common in TS+ group 
(69.6%) and by far the largest number of TS 
occurred within 30 days after PCI ("early TS") 
(17 patients or 73.9%). DES were applied in 2 
patients with late TS+, but BMS were implanted 
in all of 4 patients with very late TS+ (17.4%) 
(Table 3). 
 
Discussion 
 
Incidence of definite TS+ was 2.2% in our 
sample. These figures are similar to the results of 
the other authors (7), since its incidence varies 
from 1% to over 5%, depending on inclusion 
criteria and definition of TS+. Thus, Iqbal et al. 
found TS+ in 1.9% of patients (8), and van 
Werkum in 2.1% of patients, with a similar 
incidence of acute TS (32%), subacute (41,2%) 
and very late TS (13.5%) as in our study, while a 
late TS was observed more frequently (13,3%) 
(3). Cumulative incidence of TS+ in studies with 
DES was even higher, particularly with earlier 
generations of DES (with paclitaxel and sirolimus), 
while new DES generations (with everolimus) 
caused lower incidence of TS+ (9). Fortunately, 
the incidence of TS+ has been lower in the recent 
years because of improved stent design, use of 
higher rate of pressures and powerful DAPT 
during stent implantation (10).  
There are no significant differences in 
demographic characteristics and some risk 
factors between TS+ and TS-groups, as in the 
study by van Werkum et al. (11). However, 
smoking was significantly more present in our 
patients (60.9% vs. 21.4%, p<0.02). Also, 
STEMI was the most common presentation 
preceding TS+, which is in keeping with the 
results of other authors. It has been already 
shown that there is a difficult choice of optimal 
stent size because of large thrombotic burden 
and consequent vasoconstriction in STEMI in 
addition to hypercoagulable state. Our results 
confirmed  that patients with PCI for ACS, 
especially STEMI, were under much greater risk 
for TS+, which is in accordance with literature 
data showing that ACS is one of the main 
predictors of TS+. Also, higher NYHA class and 
low left ventricular EF were registered signifi-
cantly more often in TS+ patients compared to 
TS-  patients, as shown by other authors. Thus, 
these authors found reduced left ventricular 
function (EF <30%) twice as many in patients 
with TS+ compared to TS-  patients (16.4% vs. 
8.2%). 
Procedural complications as coronary 
artery dissection (26.1%) or greater average 
stent length (19.69 vs. 17.01mm, p<0.05), 
smaller stent diameter (2.87 vs 3.0 mm), lower 
pressure stent insufflation (14.84 vs 16.02 atm, 
p<0.05), the "underestimated lesions" and the 
use  of smaller diameter stent than optimal 
(21.7% vs 4.3%, p<0.01) were the main reasons 
for the appearance of TS+ in our study. The 
incidence of inadequate stent implantation or use 
of smaller stent than necessary was 20-30%, as 
shown by previous studies.  Therefore,  this 
percentage was even higher when it was 
assessed by intravascular ultrasound (IVUS). 
Severe calcification or large thrombotic burden 
with consequent vasoconstriction are the most 
common reasons for deployment of a stent 
smaller than necessary,  but in some cases by 
incorrect assessment of the true size of the 
coronary arteries by the operator probably (3). Acta Medica Medianae 2013, Vol.52(4)                             Clinical and angiographic characteristics of patients with stent thrombosis 
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The percentage of patients with deployed smaller 
stent would probably be higher in our study and 
similar to data from literature if IVUS was used in 
postprocedural analysis. Coronary artery dissection 
is the most common reason for TS+ revealed by 
IVUS, but this device was helpful in finding the 
cause of TS+ in even 22% of the patients (12). 
Discontinuation of DAPT or resistance to it 
caused TS in more than two thirds of cases 
similarly to the results of other authors (3,13). 
Pfisterer et al. analyzed more than 700 patients 
with implanted DES and BMS in the ratio 2:1. 
The rate of adverse events (death or myocardial 
infarction  -  IM) did not differ  between the two 
groups of patients after 18 months of follow-up, 
until some patients stopped taking clopidogrel. 
The rate of adverse events was significantly 
higher in the DES group (4.9% vs 1.3%) at that 
moment (14). The cumulative incidence of TS+ 
after 3 years of follow-up was 2% in one large 
study with 23. Five hundred patients with placed 
DES, with no difference in relation to the type of 
DES (with sirolimus vs paclitaxel). Nearly one 
third of patients (31.6%) stopped taking DAPT 
because of low compliance in 70% of these 
patients. The rest of these patients did it because 
of bleeding, surgery or allergic reaction to DAPT 
(15). A similar proportion of patients stopped 
taking aspirin and/or clopidogrela in our study 
(34.7%). Inadequate comprehension of the 
importance of regular use of DAPT seemed to be 
the main reason for cessation of taking DAPT, but 
regular use or availability of certain drugs 
particularly clopidgrel were affected by economics 
in some patients. 
A resistance to DAPT was the cause of TS 
in more than one third of patients with TS+, 
besides their poor compliance and/or financial 
resources. The first study which assessed the 
clinical significance of poor response to clopi-
dogrel ("non-responders") was on 105 patients 
with stable coronary artery disease. The authors 
found that up to 11% of patients did not respond 
to clopidogrel, and up to 26% had a partial 
response to the drug ("semi-responders"). A 
subacute TS occurred 6 days after PCI in 2 out of 
5 "non-responders” (16). Lev et al. found non-
responsiveness to aspirin, clopidogrel and dual 
nonresponsiveness in 12.7%, 24% and 47.4% of 
patients, respectively. Women with higher BMI 
(33.8kg/m2) represented the majority of patients 
with dual nonresponsiveness (to aspirin and 
clopidogrel) (17). Other authors find, however, 
resistance to aspirin, clopidogrel and dual 
resistance in 11.5%, 6% and 6% of patients, 
respectively, in more than 800 patients with 
implanted DES and definite TS in 4.4% of dual-
resistant patients (18). 
TS+ group of patients underwent PCI with 
implantation of a new stent in less than one half 
of cases (47.8%), and the others underwent 
balloon dilatation (POBA, in 47.8% of patients) 
and thrombus aspiration (in 4.4%), which results 
are similar to findings of other authors (11). 
Unfortunately, the GP IIb / IIIa inhibitors were 
often unavailable during the study period. 
There is a higher prevalence of BMS 
compared to DES in early vs very late TS, DES 
getting a greater role with elapse of time in the 
occurrence of TS. 
Spaulding et al. did not find a significant 
difference in the survival rate and cumulative 
incidence of TS after one year and after four 
years of follow-up between patients who received 
BMS (4%) and DES with sirolimus (3.6%), 
though DES dominate in the group with a very 
late  TS (19-21). A share of BMS increased 
progressively in the occurrence of very late TS, 
and was even higher, when authors considered 
the probable and possible TS besides definite TS 
(2). A greater availability and better choice of 
BES may be the reasons for more deployed BMS 
compared to DES in patients with very late TS in 
our study. 
Kastrati et al. analyzed 14 studies with 
nearly 5.000 patients comparing BMS and DES 
(with sirolimus) and showed that the incidence of 
fatal outcome and IM, as well as the overall risk 
of TS, did not differ significantly between patients 
with BMS and DES, but after the first year of 
follow up TS significantly more frequently 
presented in the BMS group. It is difficult to 
explain why the rate of TS is similar between 
BMS and DES after one year of follow-up if 
postponed endothelialization is the main mecha-
nism of delayed TS, despite the fact that BMS 
lead to faster healing of the artery wall. However, 
there was a slight increase of risk of TS in DES 
patients in a further four-year  follow-up, but 
there was no statistically significant difference 
between BMS and DES group (22,23). 
Mauri et al. found no significant difference 
in the incidence of TS between BMS and DES 
group (sirolimus and paclitaxel) after 4 years of 
follow up of more than 2.200 patients in each 
group, which is similar to our results, although 
non-availability of DES or all dimensions of DES 
contributed to it in our study, and the use of BMS 
was sometimes forced.  
The mechanism of early thrombosis after 
the use of BMS is the result of platelet activation 
and inflammatory changes that occur after stent 
deployment and the ability of stented area for 
reendothelialization after PCI. The endotheliali-
zation process is thought to be complete after 1–
4 months of BMS use. Several mechanisms have 
been proposed to explain very late TS as it 
occurs long after completing the endotheli-
alization process, such as delayed endotheli-
alization, diffuse in-stent restenosis, plaque 
disruption near the stented area and stenting of 
necrotic or ulcerated plaques. Very late TS  may 
occur more than 10 years after BMS deployment, 
although very late TS is much commonly 
described after the use of DES. Performing the 
best possible PCI is the best way to avoid this 
often fatal complication. However, a  better 
definition of optimal duration of DAPT in patients Clinical and angiographic characteristics of patients with stent thrombosis                                              Miodrag Damjanović et al. 
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with stents remains to be further developed and 
a long-term follow-up is of utmost importance 
(25). 
 
Conclusions 
 
The risk of TS is increased in patients with 
STEMI and impaired systolic function of the left 
ventricle. Discontinuation of DAPT and resistance 
to it are common reasons related to patient 
characteristics. The higher percent of stenosis of 
stented lesions, greater stent length, small stent 
diameter („underestimated lesion“), lower insuffla-
tion pressure and coronary artery dissection are 
procedure-related factors causing TS. TS occurs 
most usually in almost three-quarters of cases 
during the first 30 days after PCI, more often 
after BMS deployment. 
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KLINIČKE I ANGIOGRAFSKE KARAKTERISTIKE BOLESNIKA SA 
TROMBOZOM STENTA 
 
Miodrag Damjanović, Milan Pavlović, Svetlana Apostolović, Zoran Perišić,  
Sonja Šalinger-Martinović, Milan Živković, Nenad Božinović, Vladimir 
Miloradović, Danijela Đorđević-Radojković, Boris Đinđić, Goran Koraćević,  
Miloje Tomašević, Goran Davidović, Vera Irić-Ćupić 
 
 
Tromboza stenta (TS) je  posle perkutane  koronarne intervencije (PCI)  retka, ali 
potencijalno fatalna komplikacija, sa učestalošću od 1% do preko 5%. Faktori rizika za TS 
mogu da se podele na faktore koji su u vezi sa samim bolesnikom, sa procedurom, tipom 
stenta i karakteristikama lezije.  
U studiju je uključeno 1055 bolesnika kojima je urađena PCI tokom 2009. i 2010. 
godine i koji su praćeni naredne dve godine. Bolesnici sa sigurnom TS čine ispitivanu (TS+), 
a bolesnici bez sigurne TS kontrolnu grupu (TS-). Sigurna TS definisana je prema 
kriterijumima ARC (Academic Research Consortium). 
Sigurnu TS imalo je 23 bolesnika (2,2%). Rana TS zabeležena je kod 73,9%, kasna 
kod 8,7%, a vrlo kasna kod 17,4% bolesnika. Akutni infarkt miokarda sa ST elevacijom 
(STEMI) bio je najčešća klinička prezentacija (56,6% vs 20%, p<0,005) u ispitivanoj grupi. 
Prekid uzimanja aspirina i/ili clopidogrela (34,7%), kao i rezistencija na ove lekove 
(34,7%), NYHA klasa  ≥2  (39,1%  vs  17,1%,  p<0,02)  i  manja  ejekciona  frakcija  leve 
komore (42,3 vs 49,8, p<0,001) bili su glavni faktori TS koji se tiču samih bolesnika. Veći 
procenat  stenoze  lezija  (92%  vs  86%,  p<0,05),  veća  prosečna  dužina  stenta  (19,69  vs 
17,01mm, p<0,05), mali dijametar stenta („potcenjena lezija“) (21,7% vs 4,3%, < 0,01), 
manji pritisak insuflacije stenta (14,84 vs 16,02atm, p<0,05) i disekcija koronarne arterije 
(26,1% vs 8,6%, p<0,005) bili su signifikantni razlozi za nastanak TS. Kod bolesnika obe 
grupe primenjen je sličan tip stenta: BMS („bare metal stents) (69,6% vs 72,9%, NS) i DES 
(„drug eluting stents“) (30,4% vs 27,1%, NS).  
Bolesnici sa STEMI, kao i oni sa oslabljenom sistolnom funkcijom leve komore,  pod 
najvećim su rizikom za nastanak TS, u više od 2/3 slučajeva u prvih 30 dana nakon PCI 
(rana TS). Prekid uzimanja aspirina i/ili clopidogrela ili rezistencija na ove lekove dovode do 
TS  (rana  TS).  Veći  procenat  stenoze  lezija,  veća  dužina  stenta,  mali  dijametar  stenta 
(„potcenjena  lezija“),  manji  pritisak  insuflacije  i  disekcija  koronarne  arterije  su  najčešći 
proceduralni razlozi za nastanak TS. Tip stenta (BMS i DES) nije značajno uticao na pojavu 
TS. Acta Medica Medianae 2013;52(4):5-11. 
 
Ključne reči: perkutana koronarna intervencija, tromboza stenta 
 
 